Refractory B-Cell Non-Hodgkin Lymphoma Clinical Trials in Salt Lake City, Utah
3 recruitingSalt Lake City, Utah
Showing 1–3 of 3 trials
Recruiting
Phase 1
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah24 enrolled1 locationNCT06824701
Recruiting
Phase 2
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Mantle Cell LymphomaMarginal Zone LymphomaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah27 enrolled1 locationNCT06300528
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Lymphoma, Non-HodgkinRefractory B-Cell Non-Hodgkin LymphomaRelapsed Non Hodgkin Lymphoma
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763